Change of the serum hormone level in ultra-acute phase caused by the GnRH antagonist degarelix

Change of the serum hormone level in ultra-acute phase caused by the GnRH antagonist degarelix - Change of the hormone level by degarelix

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014958

Enrollment

Registered

2014-08-27

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Degarelix

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patholigically confirmed prostate cancer patients

Exclusion criteria

Exclusion criteria: Active urinary tract infection Severe boiding dysfunction Active other malignancies

Design outcomes

Primary

Measure	Time frame
The level of serum testosterone, Luteinizing hormone, Follicule-stimulating hormone within 24hrs after the injection of degarelix	—

Secondary

Measure	Time frame
Change of serum prostate specific antigen	—

Countries

Japan

Contacts

Public ContactGaku Arai

Dokkyo Medical University Koshigaya Hospital Department of Urology

g-arai@dokkyomed.ac.jp+81-48-965-8743

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026